These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12018459)

  • 61. Dimeric 2G12 as a potent protection against HIV-1.
    Luo XM; Lei MY; Feidi RA; West AP; Balazs AB; Bjorkman PJ; Yang L; Baltimore D
    PLoS Pathog; 2010 Dec; 6(12):e1001225. PubMed ID: 21187894
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Systems serology: profiling vaccine induced humoral immunity against HIV.
    Chung AW; Alter G
    Retrovirology; 2017 Dec; 14(1):57. PubMed ID: 29268769
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HIV-1: the confounding variables of virus neutralization.
    Nara PL; Lin G
    Curr Drug Targets Infect Disord; 2005 Jun; 5(2):157-70. PubMed ID: 15975021
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.
    Van Regenmortel MH
    Arch Virol; 2012 Jan; 157(1):1-20. PubMed ID: 22012269
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates.
    Davis D
    Vaccine; 1996 Mar; 14(4):353-4. PubMed ID: 8744564
    [No Abstract]   [Full Text] [Related]  

  • 66. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
    Heeney JL
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S53-64. PubMed ID: 15285705
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibody-based HIV-1 vaccines: recent developments and future directions.
    Montefiori D; Sattentau Q; Flores J; Esparza J; Mascola J;
    PLoS Med; 2007 Dec; 4(12):e348. PubMed ID: 18052607
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.
    Deruaz M; Moldt B; Le KM; Power KA; Vrbanac VD; Tanno S; Ghebremichael MS; Allen TM; Tager AM; Burton DR; Luster AD
    J Infect Dis; 2016 Aug; 214(4):612-6. PubMed ID: 27357340
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV.
    Van Regenmortel MHV
    Vaccine; 2017 Apr; 35(16):1985-1986. PubMed ID: 28320589
    [No Abstract]   [Full Text] [Related]  

  • 70. Multiple roles for HIV broadly neutralizing antibodies.
    Haynes BF; Burton DR; Mascola JR
    Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666399
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.
    Brandenberg OF; Magnus C; Rusert P; Günthard HF; Regoes RR; Trkola A
    PLoS Pathog; 2017 May; 13(5):e1006313. PubMed ID: 28472201
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rationale for a vaccine using cellular-derived epitope presented by HIV isolates.
    Galéa P; le Contel C; Coutton C; Chermann JC
    Vaccine; 1999 Mar; 17(13-14):1700-5. PubMed ID: 10194825
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Countering HIV - Three's the Charm?
    Margolis DM; Garcia JV
    N Engl J Med; 2018 Jan; 378(3):295-297. PubMed ID: 29342376
    [No Abstract]   [Full Text] [Related]  

  • 74. HIV specific humoral immune response in Rio de Janeiro, Brazil. The HEC/Fiocruz AIDS Clinical Research Group.
    Bongertz V; Costa CI; Guimarães ML; Soares-da-Costa MF; Grinsztejn B; Bastos FI; Pilotto JH; João Filho EC; Loureiro R; Chequer P; Telles PR; Galvão-Castro B; Morgado MG
    Mem Inst Oswaldo Cruz; 1998; 93(3):391-8. PubMed ID: 9698875
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine.
    Wagner R; Shao Y; Wolf H
    Vaccine; 1999 Mar; 17(13-14):1706-10. PubMed ID: 10194826
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.
    Gauduin MC; Allaway GP; Olson WC; Weir R; Maddon PJ; Koup RA
    J Virol; 1998 Apr; 72(4):3475-8. PubMed ID: 9525686
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prospects for passive immunity to prevent HIV infection.
    Morris L; Mkhize NN
    PLoS Med; 2017 Nov; 14(11):e1002436. PubMed ID: 29136030
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1.
    Donners H; Willems B; Beirnaert E; Colebunders R; Davis D; van der Groen G
    AIDS; 2002 Feb; 16(3):501-3. PubMed ID: 11834970
    [No Abstract]   [Full Text] [Related]  

  • 79. The road to an effective HIV vaccine.
    Baden LR; Dolin R
    N Engl J Med; 2012 Apr; 366(14):1343-4. PubMed ID: 22475599
    [No Abstract]   [Full Text] [Related]  

  • 80. Inefficacy of neutralizing antibodies against autologous lymph-node HIV-1 isolates in patients with early-stage HIV infection.
    Tamalet C; Lafeuillade A; Tourres C; Yahi N; Vignoli C; De Micco P
    AIDS; 1994 Mar; 8(3):388-9. PubMed ID: 8031520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.